Chemours Co is projected to report Q2 2026 revenue of $1.66 billion and earnings per share of $0.43, while the stock currently trades at $17.09 compared to an average analyst price target of $24.88.
The primary focus for investors is the recovery of the Titanium Technologies segment, as the market looks for signs of bottoming in global TiO2 pricing and volume demand.
Sentiment is bolstered by the company's recent $360 million land sale in Taiwan intended for debt reduction and a major $450 million PFAS settlement that addresses significant regulatory overhang. Management has provided Q2 2026 Adjusted EBITDA guidance of $220 million to $250 million, highlighting operational improvements despite continued macroeconomic uncertainty.